Opendata, web and dolomites

OrganoPlate Graft SIGNED

Organ-on-a-Chip technology for in vitro grafting and vascularisation of 3D tissues

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OrganoPlate Graft project word cloud

Explore the words cloud of the OrganoPlate Graft project. It provides you a very rough idea of what is the project "OrganoPlate Graft" about.

body    2013    unrivalled    largely    3d    differ    readiness    accurately    launched    unmet    experiments    throughput    complications    basic    points    safety    tissue    add    commercially    ftes    empower    aiding    founded    functional    50m    biology    problem    vital    cell    annual    drug    tissues    lacks    extensive    grow    organs    alternatives    options    structure    cultivation    market    mini    inside    vitro    cycle    depending    revenues    year    manipulation    solutions    settings    chip    solution    lack    models    pathology    speed    wealth    mimetas    vascularized    organ    monitored    replacement    time    proof    vessels    generates    vascularization    graft    human    projected    culture    dutch    3m    company    efficacy    employs    2020    party    therapeutics    clinical    post    outside    profitable    fte    sme    poc    employ    completely    blood    months    gt    exists    therapeutic    animal    professionals    million    organoplate    vivo    toxicity    2022    first    tumors   

Project "OrganoPlate Graft" data sheet

The following table provides information about the project.

Coordinator
MIMETAS BV 

Organization address
address: JH Oortweg 19
city: Leiden
postcode: 2333CH
website: www.mimetas.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙014˙718 €
 EC max contribution 2˙110˙303 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2021-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MIMETAS BV NL (Leiden) coordinator 2˙110˙303.00

Map

 Project objective

PROBLEM – The drug development cycle, from basic research to testing efficacy, toxicity, and safety of new therapeutics, is largely depending on animal models. However animal biology and pathology differ from human biology at crucial points. The sector is aware of the significant complications in their usage, but lacks better alternatives. Highly advanced technology exists for the culture of cell systems, organs, tumors, etc. outside the body (‘in vitro’). However, the existing culture models lack functional blood vessels – a vital structure inside the body (‘in vivo’). There is a great unmet need for better models of human biology, to speed up both basic research on human biology as well as the development of novel, much needed therapeutic solutions. SOLUTION – OrganoPlate Graft involves the development to market readiness of the first high-throughput in vitro culture method for vascularized tissue that is unrivalled by the available in vitro options. An extensive proof of concept (PoC) for this method has been obtained. The new product will be launched within 6-months post-project and, for the first time, allow for the study and manipulation of human tissues with functional human vascularization. COMPANY – Founded in 2013, the Dutch SME MIMETAS was the first party to commercially exploit organ-on-a-chip technology that enables accurately controlled and monitored in vitro cultivation 3D ‘mini-organs’. MIMETAS currently employs > 60 professionals, generates year-on year multi-million revenues, and is projected to be profitable as of 2020. RESULTS – The results of the 2-year OrganoPlate Graft project will empower Users by aiding them to grow tissues with human vascularization in vitro – enabling the replacement of a wealth of animal experiments and the design of completely novel experiments in research, development and clinical settings. OrganoPlate Graft will cost €3M, employ 10 new FTEs, and is projected to add 40 FTE and >€50M annual revenues to MIMETAS by 2022.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ORGANOPLATE GRAFT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ORGANOPLATE GRAFT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

EDITUS (2019)

Helping our customers to design smart and safe tomorrows’ communication systems

Read More  

Presque (2019)

Smart Nursing Bra

Read More